Krazati (adagrasib) — Medica
Non-small cell lung cancer (NSCLC)
Initial criteria
- age ≥ 18 years
- KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an approved test
- ONE of the following: (i) previously treated with at least one systemic regimen OR (ii) has brain metastases
Approval duration
1 year